Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial - Concepedia

Concepedia

Publication | Open Access

Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial

DOI Full Paper Access

94

Citations

28

References

2018

Year

Kausik K. Ray, Lawrence A. Leiter, Dirk Müller‐Wieland, Bertrand Cariou, Helen M. Colhoun, Robert R. Henry, Francisco J. Tinahones, Maja Bujas‐Bobanovic, Catherine Domenger, Alexia Letierce,

Diabetes Obesity and Metabolism

Abstract

In individuals with T2DM and mixed dyslipidaemia on maximally tolerated statin, alirocumab showed superiority to UC in non-HDL cholesterol reduction and was generally well tolerated.

References

	Year	Citations

Page 1